120 related articles for article (PubMed ID: 8949993)
1. Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer.
Dunn TA; Schmoll HJ; Grünwald V; Bokemeyer C; Casper J
Anticancer Drugs; 1996 Sep; 7(7):795-9. PubMed ID: 8949993
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts.
Dunn TA; Grünwald V; Bokemeyer C; Casper J
Invest New Drugs; 1997; 15(2):91-8. PubMed ID: 9220287
[TBL] [Abstract][Full Text] [Related]
3. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
[TBL] [Abstract][Full Text] [Related]
4. Amifostine protective effect on cisplatin-treated rat testis.
Lirdi LC; Stumpp T; Sasso-Cerri E; Miraglia SM
Anat Rec (Hoboken); 2008 Jul; 291(7):797-808. PubMed ID: 18543292
[TBL] [Abstract][Full Text] [Related]
5. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
6. Amifostine as a protector against cisplatin-induced toxicity in nude mice.
Johnsson A; Wennerberg J
Acta Oncol; 1999; 38(2):247-53. PubMed ID: 10227448
[TBL] [Abstract][Full Text] [Related]
7. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
Pera MF; Köberle B; Masters JR
Br J Cancer; 1995 May; 71(5):904-6. PubMed ID: 7734313
[TBL] [Abstract][Full Text] [Related]
8. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
[TBL] [Abstract][Full Text] [Related]
9. Production and pre-clinical significance of haematopoietic peptide growth factors (HPGF) in human non-seminomatous germ cell tumour cell lines.
Dunn TA; Schmoll HJ; Rie C; Hartmann K; Casper J
J Cancer Res Clin Oncol; 1998; 124(8):435-43. PubMed ID: 9750020
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice.
Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ
Eur J Cancer; 1998 Feb; 34(3):412-6. PubMed ID: 9640232
[TBL] [Abstract][Full Text] [Related]
11. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines.
Dunn TA; Schmoll HJ; Grünwald V; Bokemeyer C; Casper J
Invest New Drugs; 1997; 15(2):109-14. PubMed ID: 9220289
[TBL] [Abstract][Full Text] [Related]
12. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
13. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
[TBL] [Abstract][Full Text] [Related]
14. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol).
Schuchter LM
Eur J Cancer; 1996; 32A Suppl 4():S40-2. PubMed ID: 8976821
[TBL] [Abstract][Full Text] [Related]
15. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Treskes M; Boven E; Holwerda U; Pinedo HM; van der Vijgh WJ
Cancer Res; 1992 Apr; 52(8):2257-60. PubMed ID: 1313740
[TBL] [Abstract][Full Text] [Related]
16. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
[TBL] [Abstract][Full Text] [Related]
17. Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity.
Mueller T; Mueller LP; Holzhausen HJ; Witthuhn R; Albers P; Schmoll HJ
Histochem Cell Biol; 2010 Aug; 134(2):197-204. PubMed ID: 20532795
[TBL] [Abstract][Full Text] [Related]
18. Amifostine for protection from antineoplastic drug toxicity.
Foster-Nora JA; Siden R
Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
[TBL] [Abstract][Full Text] [Related]
19. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
van der Vijgh WJ; Korst AE
Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
[TBL] [Abstract][Full Text] [Related]
20. Advances in the management of non-seminomatous germ cell tumors during the cisplatin era: a single-institution experience.
Muramaki M; Hara I; Miyake H; Yamada Y; Kawabata G; Kamidono S
Int J Urol; 2004 Sep; 11(9):768-73. PubMed ID: 15379942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]